The efficacy of immune-modulating anti-cancer therapeutic antibodies that have been FDA-approved in recent years, such as anti-CTLA-4 and anti-PD-1, has driven growing interest in methods that provide a mechanistic understanding of drug function. Development of new mono- and combination therapies with immune-modulatory effects requires more powerful immunophenotyping techniques capable of in depth cell characterization.
During AACR’s Annual Meeting 2016, Matt Thayer, Sr. Assistant Scientist, In Vitro Operations, presented his poster session and spoke about his work with using the CT.26 murine syngeneic colorectal cancer model to develop a 10-color flow cytometry antibody panel. This panel focuses on the identification of tumor-infiltrating immune cell subsets derived from myeloid lineage precursors utilizing the high-throughput-capable 4-laser, 14-color Attune™ NxT Flow Cytometer.
该面板包括针对CD45，CD3，CD19，CD49B，CD335，CD11B，CD11C，LY-6G，LY-6C，F4 / 80和CD115的抗体的组合。通过排除淋巴谱系的细胞，Covance表明，该面板促进了天然杀伤（NK）细胞和骨髓衍生细胞的分析，包括巨噬细胞，中性粒细胞，树突状细胞（DCS）和单核细胞或粒细胞髓样衍生的抑制细胞（MMDSC和GMDSC）肿瘤和外周血的子集。
此外，该抗体组合允许更完整地分析MDSC细胞，其可以差异地表达几种疾病相关的骨髓特异性标记，包括Ly-6G，Ly-6C，F4 / 80，CD11C和CD115。该面板还用于表征控制和抗PD-L1处理小鼠之间的骨髓子集的变化。
To view more on this subject matter, please use the link below to download the entire poster. You may also联系我们有关更多信息或设置您的下一项研究。
